Actyon Discovery, Inc.
Digital drug-discovery company focused on discovering novel small-molecule therapeutics by generating ultra-large, synthetically accessible reaction spaces centered on novel ring-system scaffolds and prioritizing candidates using expert-system synthesis prediction and AI-guided selection. Selected compounds are synthesized and biologically tested via partners, third-party providers, and internal efforts.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Digital drug-discovery platform that generates ultra-large, synthetically accessible reaction spaces centered on novel scaffolds, applies expert-system synthesis forecasting and AI prioritization, and provides reaction strategies for compound synthesis and biological testing.
Digital drug-discovery platform that generates ultra-large, synthetically accessible reaction spaces centered on novel scaffolds, applies expert-system synthesis forecasting and AI prioritization, and provides reaction strategies for compound synthesis and biological testing.
Expertise Areas
- Digital drug discovery
- Cheminformatics and computational chemistry
- Lead generation and small-molecule discovery
- Synthetic accessibility prediction and virtual inventory methods
Key Technologies
- Ultra-large reaction-space generation
- Expert-system synthesis prediction (reaction transforms)
- Synthetic-accessibility virtual inventory methods
- AI-guided compound selection
News & Updates
Dr. Marc Nicklaus, noted for work on synthetic-accessibility virtual inventory approaches and cheminformatics tools, joined as Chief Scientific Officer.
Dr. Marc Nicklaus, noted for work on synthetic-accessibility virtual inventory approaches and cheminformatics tools, joined as Chief Scientific Officer.